Kezar Life Sciences Inc (KZR) Receives a Buy from Cowen & Co.

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Kezar Life Sciences Inc (KZR). The company’s shares closed yesterday at $24.

According to, Nadeau is a 5-star analyst with an average return of 8.7% and a 50.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Allogene Therapeutics Inc.

Kezar Life Sciences Inc has an analyst consensus of Moderate Buy.

See today’s analyst top recommended stocks >>

Based on Kezar Life Sciences Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.78 million. In comparison, last year the company had a GAAP net loss of $2.26 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kezar Life Sciences, Inc. develops drugs to revolutionize the treatment of autoimmune disorders. It also discovers and develops new therapies targeting protein homeostasis. The firm specializes in the areas of protein degradation and protein secretion to discover and develop novel therapies for the treatment of serious, unmet medical needs.